Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 1,481 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| ATAI Life Sciences NV | ATAI | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.06 | 3.26% | 1.90 | 08:02:38 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.84 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 18 | 1,481 | - | 1.025 - 2.85 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 08:04:23 | 50 | US$ 1.90 | USD |
ATAI Life Sciences NV Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 305.46M | 166.01M | - | 314k | -40.22M | -0.24 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
ATAI Life Sciences NV News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ATAI Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.92 | 2.07 | 1.80 | 1.89 | 971,356 | -0.02 | -1.04% |
| 1 Month | 1.97 | 2.85 | 1.76 | 2.30 | 2,417,178 | -0.07 | -3.55% |
| 3 Months | 1.78 | 2.85 | 1.58 | 2.08 | 1,717,797 | 0.12 | 6.74% |
| 6 Months | 1.22 | 2.85 | 1.025 | 1.84 | 1,433,095 | 0.68 | 55.74% |
| 1 Year | 1.87 | 2.85 | 1.025 | 1.82 | 1,097,538 | 0.03 | 1.60% |
| 3 Years | 21.00 | 22.91 | 1.025 | 3.95 | 978,171 | -19.10 | -90.95% |
| 5 Years | 2.20 | 22.91 | 1.025 | 3.89 | 870,030 | -0.30 | -13.64% |
ATAI Life Sciences NV Description
| ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany. |
